191 related articles for article (PubMed ID: 16799883)
1. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Kumekawa Y; Kaneko K; Ito H; Kurahashi T; Konishi K; Katagiri A; Yamamoto T; Kuwahara M; Kubota Y; Muramoto T; Mizutani Y; Imawari M
J Gastroenterol; 2006 May; 41(5):425-32. PubMed ID: 16799883
[TBL] [Abstract][Full Text] [Related]
2. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
Ishikura S; Nihei K; Ohtsu A; Boku N; Hironaka S; Mera K; Muto M; Ogino T; Yoshida S
J Clin Oncol; 2003 Jul; 21(14):2697-702. PubMed ID: 12860946
[TBL] [Abstract][Full Text] [Related]
3. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
Morota M; Gomi K; Kozuka T; Chin K; Matsuura M; Oguchi M; Ito H; Yamashita T
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):122-8. PubMed ID: 19327900
[TBL] [Abstract][Full Text] [Related]
4. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Ohtsu A; Boku N; Muro K; Chin K; Muto M; Yoshida S; Satake M; Ishikura S; Ogino T; Miyata Y; Seki S; Kaneko K; Nakamura A
J Clin Oncol; 1999 Sep; 17(9):2915-21. PubMed ID: 10561371
[TBL] [Abstract][Full Text] [Related]
5. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula.
Nishimura Y; Suzuki M; Nakamatsu K; Kanamori S; Yagyu Y; Shigeoka H
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):134-9. PubMed ID: 12007951
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
[TBL] [Abstract][Full Text] [Related]
7. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
[TBL] [Abstract][Full Text] [Related]
10. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
11. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Tamura T; Kuwahara A; Yamamori M; Nishiguchi K; Nakamura T; Okuno T; Miki I; Manabe Y; Sakaeda T
Int J Med Sci; 2012; 9(10):833-7. PubMed ID: 23155356
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy for esophageal cancer with malignant fistula.
Koike R; Nishimura Y; Nakamatsu K; Kanamori S; Shibata T
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1418-22. PubMed ID: 18234437
[TBL] [Abstract][Full Text] [Related]
14. Outcomes from chemoradiotherapy for patients with esophageal cancer.
Pantling AZ; Gossage JA; Mamidanna R; Newman G; Robinson A; Manifold DK; Hale PC
Dis Esophagus; 2011 Apr; 24(3):172-6. PubMed ID: 21073614
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
[TBL] [Abstract][Full Text] [Related]
16. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
17. Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer.
Zenda S; Hironaka S; Boku N; Yamazaki K; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Nishimura T
Dis Esophagus; 2008; 21(3):195-200. PubMed ID: 18430098
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcome of intensity-modulated radiation therapy for locally advanced esophageal squamous cell carcinoma.
Ge X; Yang X; Lu X; Wen W; Zhen F; Ye H; Zhu H; Cao Y; Zhang S; Cheng H; Ma J; Yang B; Dai S; Guo Q; Cai J; Sun X
Tumori; 2015; 101(2):168-73. PubMed ID: 25791535
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Yamashita H; Haga A; Takenaka R; Kiritoshi T; Okuma K; Ohtomo K; Nakagawa K
Radiat Oncol; 2016 Jan; 11():4. PubMed ID: 26781439
[TBL] [Abstract][Full Text] [Related]
20. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
Miyoshi N; Yano M; Takachi K; Kishi K; Noura S; Eguchi H; Yamada T; Miyashiro I; Ohue M; Ohigashi H; Sasaki Y; Ishikawa O; Doki Y; Imaoka S
J Surg Oncol; 2009 Apr; 99(5):302-6. PubMed ID: 19170110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
